{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-086275","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2024-10-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.076248+00:00","generated_at":"2026-05-30T18:49:35.390024+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ImmuCell reports Q3 2024 preliminary sales of $6.0M, up 11% YoY; backlog $7.3M","bullets":["Q3 2024 total sales $6.0M (+11% YoY); nine-month sales $18.7M (+51% YoY).","Twelve-month sales $23.8M (+46% YoY); production at 77% of ~$30M annual capacity.","Backlog of orders $7.3M; reflects strong demand as distributors replenish stocks.","Plans to submit Re-Tain NADA later this year after contract manufacturer resolves FDA issues.","Conference call on Nov 14, 2024 at 9:00 AM ET to discuss full Q3 results."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-086275","json":"https://secwatch.observer/filing/0001213900-24-086275.json","markdown":"https://secwatch.observer/filing/0001213900-24-086275.md","text":"https://secwatch.observer/filing/0001213900-24-086275.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000121390024086275/0001213900-24-086275-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000121390024086275/ea0217094-8k_immu.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T18:49:35.390024+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}